CABA Stock Price, Cabaletta Bio Inc Quote, Chart

Market Summary

USD12.96-0.36

Market Closed

-2.70%

CABA Stock Price

View Fullscreen

CABA RSI Chart

CABA Valuation

Market Cap

625.2M

Price/Earnings (Trailing)

-9.24

Price/Free Cashflow

-11.53

CABA Price/Sales (Trailing)

CABA Profitability

Return on Equity

-28.65%

Return on Assets

-26.68%

Free Cashflow Yield

-8.67%

CABA Fundamentals

CABA Earnings

Earnings (TTM)

-67.7M

Earnings Growth (Yr)

-33.1%

Earnings Growth (Qtr)

-26.98%

Breaking Down CABA Revenue

Last 7 days

-14.5%

Last 30 days

-22.8%

Last 90 days

-41.8%

Trailing 12 Months

60.4%

How does CABA drawdown profile look like?

CABA Financial Health

Current Ratio

15.29

CABA Investor Care

Shares Dilution (1Y)

53.92%

Diluted EPS (TTM)

-1.66

Tracking the Latest Insider Buys and Sells of Cabaletta Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 19, 2024	binder gwendolyn	acquired	11,110	1.01	11,000	see remarks
Jan 19, 2024	binder gwendolyn	sold	-215,439	19.5854	-11,000	see remarks
Dec 19, 2023	binder gwendolyn	acquired	11,110	1.01	11,000	see remarks
Dec 19, 2023	binder gwendolyn	sold	-240,789	21.8899	-11,000	see remarks
Nov 20, 2023	binder gwendolyn	acquired	11,110	1.01	11,000	see remarks
Nov 20, 2023	binder gwendolyn	sold	-196,014	17.8194	-11,000	see remarks
Oct 19, 2023	binder gwendolyn	acquired	11,110	1.01	11,000	see remarks
Oct 19, 2023	binder gwendolyn	sold	-146,921	13.3564	-11,000	see remarks
Sep 19, 2023	binder gwendolyn	sold	-193,220	17.5654	-11,000	see remarks
Sep 19, 2023	binder gwendolyn	acquired	11,110	1.01	11,000	see remarks

Which funds bought or sold CABA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.02	-87,000	20,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	136,997	415,751	-%
Apr 19, 2024	DENALI ADVISORS LLC	unchanged	-	-97,572	295,138	0.09%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-1,000	1,000	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-26,422	-	-%
Apr 11, 2024	CHURCHILL MANAGEMENT Corp	reduced	-5.57	-325,283	795,098	0.01%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	-1,477	4,470	-%
Apr 05, 2024	GAMMA Investing LLC	reduced	-78.57	-236	51.00	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-12.21	3,700	15,663	-%

Are Funds Buying or Selling CABA?

Are funds buying CABA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CABA

No. of Funds

Unveiling Cabaletta Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	commodore capital lp	4.4%	1,900,000	SC 13G/A
Feb 14, 2024	lynx1 capital management lp	4.99%	2,139,644	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	6.4%	2,563,952	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	3.4%	1,457,626	SC 13G/A
Feb 14, 2024	alger associates inc	7.8%	3,326,401	SC 13G/A
Feb 13, 2024	bain capital life sciences opportunities iii, lp	4.7%	2e+06	SC 13G/A
Feb 13, 2024	nichtberger steven	5.4%	2,668,756	SC 13G/A
Feb 12, 2024	flynn james e	3.60%	1,543,477	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	9.47%	3,864,475	SC 13G/A

Recent SEC filings of Cabaletta Bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	S-3ASR	S-3ASR
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 20, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Cabaletta Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Cabaletta Bio Inc News

Latest updates

Cabaletta Bio Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	46.4%	254	173	185	103	117	92.00	102	114	126	123	107	107	115	122	128	135	141	75.00	34.00
Current Assets	47.1%	244	166	178	96.00	109	88.00	99.00	111	125	121	105	106	114	119	123	134	141	72.00	34.00
Cash Equivalents	67.3%	193	116	128	94.00	82.00	61.00	47.00	60.00	122	118	99.00	97.00	101	109	112	131	136	71.00	33.00
Net PPE	27.7%	3.00	2.00	2.00	3.00	3.00	3.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-
Liabilities	41.2%	17.00	12.00	10.00	12.00	12.00	-	-	-	8.00	-	-	-	-	-	-	-	-	-	-
Current Liabilities	50.7%	16.00	11.00	8.00	9.00	9.00	6.00	6.00	7.00	8.00	6.00	6.00	4.00	5.00	4.00	3.00	3.00	3.00	3.00	1.00
Shareholder's Equity	46.8%	236	161	174	92.00	105	86.00	96.00	107	118	117	101	103	110	118	125	132	138	-	-
Retained Earnings	-9.8%	-233	-212	-195	-181	-165	-149	-138	-125	-112	-98.70	-87.14	-76.00	-66.30	-56.99	-48.60	-40.44	-32.96	-27.56	-12.45
Additional Paid-In Capital	25.7%	469	373	370	273	270	236	234	232	231	215	188	179	176	174	173	172	171	1.00	2.00
Shares Outstanding	14.8%	48.00	42.00	40.00	31.00	29.00	29.00	29.00	29.00	29.00	28.00	25.00	24.00	-	-	-	-	-	-	-
Float	-	-	-	494	-	-	-	29.00	-	-	-	205	-	-	-	214	144	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-30.5%	-16,448	-12,604	-11,889	-12,608	-12,131	-9,914	-11,526	-12,809	-10,515	-8,344	-6,580	-8,670	-9,173	-5,024	-7,642	-4,931	-7,883	-2,076	-3,821	-2,265	-
Share Based Compensation	1.4%	3,051	3,009	2,803	2,480	1,578	1,731	1,777	1,811	1,601	1,508	1,385	1,310	1,321	1,127	1,067	873	819	569	416	496	-
Cashflow From Investing	1847.7%	1,136	-65.00	-48,142	24,620	-316	23,908	-898	-49,911	849	1,770	1,027	2,353	1,891	1,471	-11,117	-226	-273	-40.00	-200	-180	-
Cashflow From Financing	94848.0%	93,049	98.00	94,258	226	32,891	-	40.00	51.00	13,628	25,339	7,771	2,165	32.00	135	-147	-44.00	73,319	-2,101	-956	49,663	-

CABA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 55,424	$ 39,300
General and administrative	19,236	14,839
Total operating expenses	74,660	54,139
Loss from operations	(74,660)	(54,139)
Other income:
Interest income	6,985	1,164
Net loss	(67,675)	(52,975)
Other comprehensive income (loss):
Net unrealized income (loss) on available-for-sale investments, net of tax	86	(47)
Net comprehensive loss	$ (67,589)	$ (53,022)
Net loss per share of voting and non-voting common stock, basic	$ (1.65)	$ (1.81)
Net loss per share of voting and non-voting common stock, diluted	$ (1.65)	$ (1.81)

CABA Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 193,238,000	$ 81,607,000
Short-term investments	48,011,000	24,940,000
Prepaid expenses and other current assets	3,241,000	2,287,000
Total current assets	244,490,000	108,834,000
Property and equipment, net	2,541,000	2,578,000
Operating lease right-of-use assets	4,910,000	4,991,000
Other assets	1,709,000	565,000
Total Assets	253,650,000	116,968,000
Current liabilities:
Accounts payable	4,547,000	2,463,000
Accrued and other current liabilities	7,887,000	4,847,000
Operating lease liabilities, current portion	3,560,000	2,179,000
Total current liabilities	15,994,000	9,489,000
Operating lease liabilities, net of current portion	1,458,000	2,959,000
Total Liabilities	17,452,000	12,448,000
Commitments and contingencies (see Notes 6 and 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 or 2022	0	0
Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2023 and December 31, 2022; 47,823,232 (46,378,937 voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023 and 29,445,134 (27,584,375 voting and 1,860,759 non-voting) shares issued and outstanding as of December 31, 2022	0	0
Additional paid-in capital	469,396,000	270,129,000
Accumulated other comprehensive income (loss)	39,000	(47,000)
Accumulated deficit	(233,237,000)	(165,562,000)
Total stockholders’ equity	236,198,000	104,520,000
Total liabilities and stockholders’ equity	$ 253,650,000	$ 116,968,000

About Cabaletta Bio Inc

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CEO	Dr. Steven A. Nichtberger M.D.
WEBSITE	cabalettabio.com
INDUSTRY	Biotechnology
EMPLOYEES	77

Cabaletta Bio Inc Frequently Asked Questions

What is the ticker symbol for Cabaletta Bio Inc? What does CABA stand for in stocks?

CABA is the stock ticker symbol of Cabaletta Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cabaletta Bio Inc (CABA)?

As of Wed Apr 24 2024, market cap of Cabaletta Bio Inc is 625.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CABA stock?

You can check CABA's fair value in chart for subscribers.

What is the fair value of CABA stock?

You can check CABA's fair value in chart for subscribers. The fair value of Cabaletta Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cabaletta Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CABA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cabaletta Bio Inc a good stock to buy?

The fair value guage provides a quick view whether CABA is over valued or under valued. Whether Cabaletta Bio Inc is cheap or expensive depends on the assumptions which impact Cabaletta Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CABA.